Filing excerpt
In April 2025, we announced the FDA approved UPLIZNA for the treatment of Immunoglobulin G4-related disease (IgG4-RD) in adult patients.
sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htmRead the full source
Amgen10-K: Product launch
Amgen secured two new FDA approvals for UPLIZNA in 2025 for rare diseases
What happened
Amgen is launching UPLIZNA for two new indications (IgG4-RD and gMG) following FDA approvals in April and December 2025. This requires significant go-to-market investment in marketing, sales force education, and patient support programs for these new patient populations.
Source
Other signals in this filing (4)
- Product launchAmgen running six global Phase 3 studies for new weight-loss drug, MariTideProduct launch
- Data investmentAmgen launches six global Phase 3 studies for its new weight-loss drug, MariTideData investment
- Market expansionAmgen received European Commission approval for TEPEZZA in June 2025, expanding into the EU marketMarket expansion
- Competitor namedAmgen names key partners and M&A counterparties including Kyowa Kirin, Takeda, and Bristol Myers SquibbCompetitor named
Extracted by Autobound
From the Signal API record- Signal
- 10-K: Product launch
What this signalsFilings often name leadership changes, deals and spending plans.
- Period
- FY2025
- Fiscal year end
- 12/31
- Filed
- Feb 13, 2026
More from Amgen
- PatentsAmgen was granted a patent for a drug-delivery device.Patents
- RedditAmgen closed its department for managing clinical trial biospecimens and replaced dedicated staff with an outsourced team in India, resulting in significant service delays.Reddit
- In developmentSjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2...In development
- IntegrationLeading Biotech Selects Veeva Vault CRM GloballyIntegration
- PartnershipAmgen Seeks Korean Partners in AI Drug Discovery, ObesityPartnership
- RevenueGlobal DLL3 Targeted Therapies Market 2026-2030: Profiles Amgen, Zai Lab, Boehringer Ingelheim and Phanes TherapeuticsRevenue
More 10-K signals at other companies
- SEC 10-KAdvanced Biomed Inc.Advanced Biomed files for 10-K extension due to incomplete financial audit.SEC 10-K
- SEC 10-KBiomerica, Inc.Biomerica Appoints New Principal Financial Officer Xiaoxuan Qu Effective August 2026SEC 10-K
- SEC 10-KCleanCore Solutions, Inc.Pivoting to AI data centers with $100M in new funding for Minnesota projectSEC 10-K
The full record
From the Signal API recordDetails
- CIK
- 318154
- Accession number
- 0000318154-26-000010
- Timeframe
- Current year
- Filing year
- 2026
- Why it matters
- Go-to-market support
- Signal category
- Strategic
Topics and mentions
Regions named
- United States
Extraction
- Confidence
- High
- Relevance
- 80%
- Sentiment
- Positive
- Detected
- Feb 17, 2026
- signal_type
sec-10k- signal_subtype
productLaunch
Use this data
Get every 10-K signal for Amgen and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”
Send it to your own tools
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/45cde32f-ce3b-4241-8b89-bb9b37132a03 returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.
{
"signal_id": "45cde32f-ce3b-4241-8b89-bb9b37132a03",
"signal_type": "sec-10k",
"signal_subtype": "productLaunch",
"detected_at": "2026-02-17T06:28:58.463+00:00",
"company": {
"name": "Amgen",
"domain": "amgen.com"
},
"data": {
"detail": "Amgen is launching UPLIZNA for two new indications (IgG4-RD and gMG) following FDA approvals in April and December 2025. This requires significant go-to-market investment in marketing, sales force education, and patient support programs for these new patient populations.",
"metrics": {
"timeframe": "current_year"
},
"summary": "Amgen secured two new FDA approvals for UPLIZNA in 2025 for rare diseases",
"excerpts": "In April 2025, we announced the FDA approved UPLIZNA for the treatment of Immunoglobulin G4-related disease (IgG4-RD) in adult patients.",
"relevance": 0.8,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm",
"filing_date": "2026-02-13",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Go-to-market support",
"signal_category": "strategic",
"regions_mentioned": [
"United States"
]
}
}
curl https://signals.autobound.ai/v1/signals/45cde32f-ce3b-4241-8b89-bb9b37132a03 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"amgen.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.